<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112563">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01819766</url>
  </required_header>
  <id_info>
    <org_study_id>Exact Sciences 2013-01</org_study_id>
    <nct_id>NCT01819766</nct_id>
  </id_info>
  <brief_title>Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease</brief_title>
  <acronym>OCEANIA</acronym>
  <official_title>Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exact Sciences Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exact Sciences Corporation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the performance of the Exact IBD-ACRN surveillance test to
      detect colorectal cancer (CRC) and colorectal neoplasia in patients with inflammatory bowel
      disease (IBD).   Patients with an IBD diagnosis for at least eight years or diagnosis of
      primary sclerosing cholangitis (PSC) and who are eligible for CRC screening are eligible to
      participate in this study. Enrolled subjects will collect a stool sample for the Exact
      IBD-ACRN surveillance test. Subjects must have undergone colonoscopy no more than 90 days
      prior to enrollment and will undergo colonoscopy or surgical intervention within 60 days of
      enrollment. Tissue diagnosis of CRC will be established by histopathologic examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, cross sectional, multi-center study to determine the sensitivity and
      specificity of the Exact IBD-ACRN surveillance test for detecting CRC alone and in
      combination with high grade dysplasia (HGD) and low grade dysplasia (LGD) associated with
      IBD and advanced adenoma in IBD patients with disease duration greater than 8 years or PSC
      diagnosis. Enrolled subjects will provide a single stool sample for the Exact IBD-ACRN
      surveillance test, no sooner than 7 days following their most recent pre-enrollment
      colonoscopy, within 30 days of enrollment and prior to initiating bowel prep for either the
      post-enrollment colonoscopy (surveillance or repeat), or surgical intervention. Stool
      samples will be tested using the Exact IBD-ACRN surveillance test and results compared to
      the colonoscopy and corresponding diagnostic histopathology results from biopsied, and any
      subsequently excised, lesions to establish sensitivity and specificity of the Exact IBD-ACRN
      surveillance test. All post-enrollment colonoscopies or surgical interventions must be
      performed within 60 days of enrollment.

      The primary objective of this study is to determine the sensitivity and specificity of the
      Exact IBD-ACRN surveillance test for CRC in IBD patients with disease duration of at least
      eight years or diagnosis of PSC. Tissue diagnosis of CRC will be established by
      histopathology examination. The secondary objective is to determine the sensitivity and
      specificity of the Exact IBD-ACRN surveillance test to detect ACRN in IBD patients with
      disease duration of at least eight years or diagnosis of PSC.

      Enrollment will continue until at least 30 CRC; 20 HGD and 240 negative subject samples have
      been obtained. There is no specific recruitment goal for IBD associated LGD or LGD
      associated with advanced adenoma (AA).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC.</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>With comparison to the colonoscopy results and histopathologic diagnosis of all lesions discovered during colonoscopy and either biopsied or removed during or subsequently removed after colonoscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine Sensitivity and Specificity of the Exact Sciences IBD-ACRN screening test for CRC and HGD.</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects with colonoscopic findings of CRC and/or high grade dysplasia (HGD) will be considered to have a positive outcome for composite CRC-HGD sensitivity calculations.  Subjects with negative colonoscopic findings will be considered to have a negative outcome.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Inflammatory Bowel Disease (IBD)</condition>
  <condition>Primary Sclerosing Cholangitis (PSC)</condition>
  <condition>Colorectal Neoplasms</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>IBD or PSC</arm_group_label>
    <description>Subjects will be men and women, 18 to 84 years of age, inclusive, who are at increased risk of developing colorectal cancer.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Residual samples may be archived for further research.  Clinical data and samples will be
      kept in a manner that preserves anonymity of the subject.  Specimens will be stored in a
      commercial biorepository contracted by Exact Sciences or at Exact Sciences and may be used
      for future research.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have diagnosed IBD with duration of at least eight years, or a diagnosis or
        PSC.  Also, have either a histopathological diagnosis of high grade dysplasia or
        colorectal cancer resulting from colonoscopy preceding enrollment or for whom a
        surveillance colonscopy is indicated.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18-84 years of age, inclusive.

          -  Diagnosis of IBD for at least eight years (or any duration with a diagnosis of HGD or
             CRC), or diagnosis of PSC with IBD of any duration, prior to enrollment date of this
             study.

          -  Must be a candidate for a surveillance colonoscopy, with the intention of
             CRC/dysplasia surveillance, or a candidate for surgical intervention based on prior
             histological confirmation of HGD or CRC.

          -  Written informed consent document signed and dated by the subject or legally
             acceptable representative.

        Exclusion Criteria:

          -  Any condition that in the opinion of the investigator should preclude participation
             in the study.

          -  A history of aerodigestive tract cancer.

          -  Prior colorectal resection, except ileocolic resection in Crohn's disease patients.

          -  IBD limited only to the rectum and without a concurrent PSC diagnosis.

          -  Subject has participated in any clinical study within the previous 30 days wherein an
             investigational compound or device was, or may be, introduced into the subject.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Itzkowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Statz, MS</last_name>
    <phone>608-284-5674</phone>
    <email>sstatz@exactsciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Few</last_name>
      <phone>480-342-2131</phone>
      <email>Few.Joy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Russell Heigh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Escobar</last_name>
      <phone>305-243-3767</phone>
      <email>c.escobar3@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Sussman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Arrieta</last_name>
      <phone>773-702-5382</phone>
      <email>rarrieta@surgery.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>David Rubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prachi Chakradeo</last_name>
      <phone>312-942-9203</phone>
      <email>Prachi_S_Charadeo@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Ece Mutlu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asantewaa Ture</last_name>
      <phone>847-570-3708</phone>
      <email>ature@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Eugene Yen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Williams</last_name>
      <phone>225-231-8737</phone>
      <email>rwilliams@dhcla.com</email>
    </contact>
    <investigator>
      <last_name>Prasad Alapati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MGG Group, Co. Inc./Chevy Chase Clinical Research</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexa White</last_name>
      <phone>301-654-2521</phone>
      <phone_ext>2106</phone_ext>
      <email>alexa.white@capitaldigestivecare.com</email>
    </contact>
    <investigator>
      <last_name>Robert Hardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Detroit Clinical Research Center, PC</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Amin</last_name>
      <phone>248-716-7011</phone>
      <email>sonia.amin@dcrc.us</email>
    </contact>
    <investigator>
      <last_name>Steven Katzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Simonson</last_name>
      <phone>949-224-2852</phone>
      <email>simonson.julie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>John Kisiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Digestive and Liver Diseases, Inc</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bell</last_name>
      <phone>573-581-7196</phone>
      <email>Jennifer.Bell@gutdoc.us</email>
    </contact>
    <investigator>
      <last_name>Glenn Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Research Associates of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Villagra</last_name>
      <phone>212-824-7804</phone>
      <email>cristina.villagra@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Itzkowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asheville Gastroeneterology Associates</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tonya Jones</last_name>
      <phone>828-254-0881</phone>
      <email>tonya.jones@ashevillegastro.com</email>
    </contact>
    <investigator>
      <last_name>William Harlan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Logan</city>
        <state>Utah</state>
        <zip>84341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Medical Research</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Robinson</last_name>
      <phone>434-455-8661</phone>
      <email>m.robinson@gastrocentralva.com</email>
    </contact>
    <investigator>
      <last_name>Larry Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Richie</last_name>
      <phone>608-262-5404</phone>
      <email>kr2@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Reichelderfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wisconsin Center for Advanced Research</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Anderson</last_name>
      <phone>414-908-6630</phone>
      <email>KathyA@wigia.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Geenen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>Colorectal Neoplasm</keyword>
  <keyword>Intestinal Neoplasms</keyword>
  <keyword>Gastrointestinal Neoplasms</keyword>
  <keyword>Digestive System Neoplasms</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Primary Sclerosing Cholangitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
